

ABN 26 104 014 379  
85 Brandl St  
EIGHT MILE PLAINS Q 4113  
P: (07) 3295 0507  
F: (07) 3341 4200  
www.injet.com.au

**INJET DIGITAL AEROSOLS LIMITED**

---

Dear Shareholder,

I am happy to enclose the InJet Digital Aerosols Limited Annual Report for the year ending 30 June 2009 as well as the Notice for the upcoming Annual General Meeting.

I would also like to take this opportunity to remind you about the current capital raising. You would have recently received a Rights Issue document which outlines the current status of the company and the need for additional funding.

The following extract from the Rights Issue outlines the strategy being pursued by the InJet Board:-

*"In June I travelled to Japan with an advisor to InJet, Dr Peter Corr, to discuss with Canon an arrangement which would allow InJet to conduct clinical trials using the Canon device. Dr Corr, the retired Senior Vice President, Science & Technology at Pfizer, and now General Partner at Celtic Therapeutics in the United States, has considerable experience in the delivery of drugs via inhalation and has offered to assist InJet with a planned clinical trial program.*

*The transaction InJet has put to Canon involves Canon sub-licensing their inhalation device and associated technology to an American-based third party to allow them to conduct clinical trials, and develop intellectual property, using a range of existing pharmaceuticals. InJet would then seek to obtain a sub -license from the American entity and conduct its own clinical trials and develop its own new intellectual property related to the delivery of existing pharmaceuticals using the Canon device. The involvement of the American entity as licensee from Canon is vital due to their experience in this field, their contacts with pharmaceutical companies and their ability to sell the technology at the completion of clinical trials. It is at this point that InJet would receive royalty or other payments associated with the sale of the technology.*

*The benefits to InJet of being able to develop its own therapeutics, to be delivered by the Canon device, are potentially substantial. It will allow InJet to develop new intellectual property, which if proved to be a success in clinical trials, could provide a new and significantly more efficient method of delivery for a wide range of existing drugs relative to existing methods. InJet would then seek to license its technology to pharmaceutical companies in return for royalties or sell the technology outright. Importantly, InJet would also receive royalties on therapeutics developed and subsequently commercialised by the proposed American licensee utilising the Canon device. It is possible that many therapeutics can be delivered utilising the Canon device and therefore InJet could receive royalties or other payments for each therapeutic developed.."*

I cannot emphasize enough the fact that we need the support of each and every shareholder, both large and small, to secure the company's future. We are seeking to raise a minimum of \$125,000, and require approximately \$300,000 to meet the ongoing costs of the company for the next 12 months.

I encourage all shareholders to take up their entitlement in the Rights Issue and consider subscribing for additional shares above their entitlement. Please keep in mind that the 'entitlement' portion of the Offer closes on October 9, by which time we must have raised the minimum \$125,000 amount.

Thank you once again for your support of the company.

Yours sincerely,

*Michael Monsour*

DR MICHAEL MONSOUR  
Chairman